Prev Close | 3.39 |
Day Low/High | 3.31 / 3.45 |
52 Wk Low/High | 2.06 / 5.95 |
Prev Close | 3.39 |
Day Low/High | 3.31 / 3.45 |
52 Wk Low/High | 2.06 / 5.95 |
Exchange | NASDAQ |
Shares Outstanding | 215.21B |
Market Cap | 729.55M |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
I will not be writing tomorrow but you will be in the very capable hands of "Meet" Bret Jensen on Wednesday. "Biotech Wednesday?" It's a hot group! Memo to Bret -- what are your thoughts on FibroGen , ZIOPHARM Oncology and Intrexon ? Thanks Broth...
I am not sure if this has broader consequences, but biotech (especially of a speculative -- kind) is spitting the bit, again today. I have already mentioned Allergan AGN (which I am buying now). Celgene CELG and Gilead Sciences GILD can't rally ei...
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have to prepare for my Tulane trip. So let's move to the abbreviated Monarc...
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as its vacation time at the Kass household and I want to take a swim with my fam...
For the first time in six years the DJIA fell for the eighth consecutive day. That said the Nasdaq has risen in ten of the last thirteen trading sessions as Donald Trump may be making volatility and uncertainty great again. (For that divergence and ...
Risk happens fast. Most don't short and shouldn't short -- it's a game that requires volumes of risk control. However, I would continue to maintain well above-average cash positions. Today was not a benign event, in my view. Nor was it likely a ...
The stock is poised for an upside breakout.
I wanted to start by congratulating El Capitan for his 12th anniversary for Mad Money tonight. Like the Energizer Bunny, he keeps going and going... HIgh yield gets junky -- despite protestations from Merrill's junk department! I have been warning ...
"As to the markets, it trades like participants are sleeping off hangovers from partying hard during last night's Super Bowl thriller." -- "Is Another Lesson Soon to be Learned?" With such little price action it seemed like a snore fest (see above...
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
"Well, they call you lady luck But there is room for doubt At times you have a very un-lady-like way Of running out..." -- Guys and Dolls, Luck Be A Lady (Frank Sinatra) Trump will not likely Make Twitter Great Again. I, bear. Explaining my pr...
Donald Trump may make illiquidity, volatility and uncertainty great again. More "Penneys" from heaven, an analysis of the company's quarterly release. Trade of the Week -- short Apple . Here and here. I sold my retail long rentals for sick ...
What stocks have changed direction in the past week.
My fellow Americans and Real Money Pro subscribers: Politics will weigh on the markets during the months leading up to the election. What, me, worry? Bank of America reports there is more than $13 trillion in negative-yielding sovereign debt now. T...
Following a 40% decline, now looks good for scaling into the stock.
Profit-taking results in a weak close.
Attention turns to earnings and away from Greece, Fed.
Here's how to lock in gains on risky small-cap biotechnology stocks.
When to take profits is a tricky but important decision.
Awaiting Yellen, but some churn wouldn't hurt.
Fighting this market isn't a money maker.
Fibrocell Science and Prothena have several 'shots on goal.'
It may not feel intuitive to embrace this market, but it works.
Speculative growth investors might want to test the water.
Higher home prices rallies stock investors, while Ziopharm does not cure cancer and Buffett picks up goldman stock - details from TheStreet's Debra Borchardt.
Ziopharm, AP Pharma and Biogen Idec will headline a very big week of approval decisions, Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg.